New drug for brain tumors tested in everyday clinics

NCT ID NCT07240662

Recruiting now Knowledge-focused Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 150 adults with slow-growing IDH-mutant grade 2 gliomas who are taking vorasidenib after surgery. Researchers will track quality of life, seizures, and tumor response in routine German clinics. The goal is to see how well the drug works outside of strict trial settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vorasidenib (oral drug)
What this could lead to: If successful, this study could show how vorasidenib affects daily life and seizures in real-world settings, guiding better care for glioma patients.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary and won't confirm long-term benefits or risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 2 glioma grade II glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
RECRUITING

Heidelberg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.